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Background: Projections of the national burden of cancer play a key role in planning cancer control programmes
and investments. We present projections of cancer incidence rates and cases for the period up to 2015-2019 in
Switzerland.
Methods: Projections were based on cancer incidence data estimated from cancer registries for the 1989-2009
periods and demographic projections of the Federal Statistical Office. Age-specific incidence rates were modelled as
a function of age, period-birth cohort using NORDPRED.
Results: Up to 2019 the incidence of all cancers combined is expected to decrease slightly for both sexes.
Nevertheless, the overall number of cases is predicted to increase. The number of male cancer cases will increase
by 30%, from 20005 in 2005-2009 to 25910/year in 2015-2019. For females the number will increase by 20%, from
16913 to 20359/year in 2015-2019. Changes in the population size and structure will be responsible for most of the
increase. Among men, the largest increase is observed for melanoma (+54%), thyroid (+45%), non-Hodgkin
lymphoma (+43%), and prostate (+37%). Prostate cancer will contribute with 8083 cases, colorectal cancer with
2908 and lung cancer with 2791. For women, cases of lung and oral cavity cancers will increase by +48% and
+38%, respectively; those of thyroid by +45% and non-Hodgkin lymphoma by +36%. The sites with the most cancer
predicted are breast (5870), colorectal and lung (over 2000 each), melanoma (1341) and corpus uteri (1040). The
overall annual cancer burden predicted for 2015-19 is of 46269 new cases in Switzerland.
Conclusions: Substantial investments appear to be needed in Switzerland cancer services to meet and fill absolute
increased demand driven by aging population.
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Estimating the rates of cancer at future time-points at a
national level is essential to plan for future services and
allocation of resources and to help establish and evaluate
cancer control programmes.
The main determinants of future burden of cancer in a
population are changes in a country’s demography and var-
iations of exposure to cancer risks and preventive factors
[1]. As the great majority of cancers occur more commonly
in older adults, the aging of the population in developed
countries predicts an increase in the absolute number of
cancer cases. More difficult is to correctly predict changes
in the profile of cancer burden as a result of variations in* Correspondence: elisabetta.rapiti@unige.ch
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unless otherwise stated.aetiological factors or proposed interventions. In fact, at
present we lack knowledge of the factors that drive trends
for most cancers.
Switzerland’s population is older and people live longer
than almost anywhere else in the world [2]. At the same
time, lifestyle changes today predict a rising of health
risks within the Swiss population in the future [3]. Both
these factors hold the prospect of an increasing demand
on the health system, particularly in dealing with chronic
diseases such as cancers. The Swiss health system with
its universal coverage, and high levels of access to ser-
vices, is high-performing with particularly strong hos-
pital care delivery. It will, nevertheless, require adapting
to the challenges of the future to ensure an optimal mix
between prevention, promotion and treatment.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Trend chosen to project the common drift
parameter D accounting for the linear component of the
trend in period and cohort by cancer site
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a Average: average trend over entire prediction base; Recent: average trend
from last 10 years.
b Constant age specific incidence rates of last observed period (2005-2009).
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http://www.biomedcentral.com/1471-2458/14/102In this study, we estimated for the first time the incidence
for all cancers in Switzerland over the period 2010-2019. We
used the age-period-cohort model with a power link func-
tion that relies entirely on the extrapolation of the recorded
rates in the past and on the forecasted population data.
Methods
Incidence Data
For our study we used the cancer incidence figures pro-
vided by the National Institute for Cancer Epidemiology
and Registration (NICER). NICER regularly estimates na-
tional cancer figures based on the data provided annually
by the cantonal registries and for those regions of
Switzerland not covered by cancer registration the numbers
are extrapolated [4].
For our study, we used the number of cases for the years
1985 to 2009 (by 1985 cancer registries covered approxi-
mately 50% of the Swiss population). Data were aggregated
into five 5-year periods (1985-1989 to 2005-2009) and
eighteen 5-year age groups (0-4 to 85+) by sex. We consid-
ered all invasive cancers combined and 12 major individual
cancer sites according to the Classification of Diseases,
10th Revision/ICD10 codes [5] (Table 1). By subtracting
from the number of all cancers combined the number of
cases from the 12 specific cancer sites we obtained the
category “other cancers”.
Population data
For the demographic evolution of the Swiss population
by 2019 we used the reference scenario called "average
(A-00-2010)” published in 2010 by the Swiss Federal
Statistical Office. This scenario hypothesizes in 2060 a
stabilization of the fertility rate at 1.5 children/woman,
the life expectancy at 86 years for men and 90 years for
women, and a net migration of 23000 people [6].
Modelling of incidence
To calculate cancer incidence projections we used
NORDPRED [7].
As recommended by Moller et al. [8], we used the age-
period-cohort model with a power link function. The
model is as follows:
Rap ¼ Aa þ D⋅pþ Pp þ Cc
 5
where Rap is the incidence rate in age group a and period
p, Aa is the parameter attributable to the age group a, D
is the common drift parameter accounting for the linear
component of the trend in period and cohort, Pp is the
nonlinear effect attributable to the period p, and Cc is the
nonlinear effect attributable to the cohort c.
We chose the lower age limit as the smallest age group
for which all models converged for each cancer site:
35-39 years for men and 20-24 years for women.Projections for age groups below this limit were based on
average rates in the last 10 years (the two last periods).
The number of periods in the prediction base was
chosen as the greatest, i.e. five 5-years periods.
The parameters of the model for projected rates were
derived as described for the Nordic countries [7,8] as
follows. The age component A was projected directly.
The nonlinear cohort effects C were projected directly
for known cohorts and taken equal to the last estimated
effect in the model for new cohorts. The non-linear
period effects P were taken to equal the last estimated
effect in the model for all future periods. The linear drift
D was assumed to continue, but with some reduction in
the later prediction periods. This allows reducing the
impact of current trends in the projections. So, we added
D and 0.75D to the first and second new periods.
Moreover, the projection of the drift is influenced by
older trends. If there were significant sharp changes in
the historical rates, projections based on the entire set of
historical rates would be inaccurate. The test for depart-
ure from a linear trend consisted of checking the signifi-
cance of S in the following model:
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In cases where S was significant, we used only the
trend in the most recent 10 years to project the drift
component D. Whether average or recent trend was
used is shown in Table 1.
In order to take into account recent changes in inci-
dence rates due to modifications in screening behav-
iours, cancer of the prostate and breast were not based
on extrapolation of past incidence trends as such. In
many high income countries, including Switzerland,
after a dramatic increase in prostate cancer incidence,
result of the widespread introduction of prostate-specific
antigen (PSA) testing, trends started to stabilize in most
recent years [9]. For this reason, we modelled prostate
cancer projections assuming that the rates observed in
the most recent period, 2005–09, would remain un-
changed in future periods [10,11].
To account for the effect of the introduction of orga-
nized screening programs for women 50 to 69 in some
cantons during the study period, for breast cancer we fit-
ted the period-cohort models separately to three age
groups: <50, 50-69 and >69.
We fitted models for nine major cancer sites in males
and for 11 in females plus one for “other cancers” for
each sex. The projections for “all cancers” were obtained
as a sum of the individual site projections. Finally, pro-
jected incidence rates were then calculated based on the
resulting models. Age-standardized incidence rates were
calculated using the European standard population.
The percent change in cancer incidence counts over
the projection period was separated into the contribu-
tion from change in cancer risk and the contribution
from change in demographics (size and age of popula-
tion). The portion of the change due to change in risk
was calculated by subtracting the number of cases that
would result from multiplying current incidence by the
estimated future population from the estimated number
of future cases. Similarly, the portion of the change due
to change in population was calculated by subtracting
the current number of cases from the number of cases
that would result by multiplying the current incidence
and the estimated future population.
Results
Table 2 presents the actual age-standardized rates and
number of cases for 2005-2009 and those projected for
2015-2019 in Switzerland by cancer site and by sex.
Figure 1 presents actual and projected rates for all
cancer and individual cancer sites. Both crude and age-
standardized rates are presented. The change in age-
standardized rates approximates to the change in risk,
while the change in crude rates includes, in addition,
the effects of an ageing population.The predicted cancer burden in 2015-2019, except for
non-melanoma skin cancers, is of 46269 new cases/year.
Most importantly, the total number of cancer cases for
men goes from 20005/year in 2005-2009 to 25910/year
in 2015-2019, and for women from 16913 to 20359. The
increase among men amounts to +30% with +34% due
to the impact of demographic changes and a reduction
of -5% due to changes in cancer risk. Among women,
the overall increase is of +20%, basically entirely due to
the demographic change, while almost no change in can-
cer risk is predicted (-1%). For all the cancer sites, an
increase in the number of cases from 2005-2009 to
2015-2019 is predicted in both sexes. This increase is
always attributable to the demographic changes and only
for some sites to an increase of cancer risk as well. For
many sites we observe a decrease in the cancer risk,
however, this decrease is usually not strong enough to
outweigh the increase due simply to the demographic
growth.
The standardized incidence rates for all cancers com-
bined (excluding non-melanoma skin cancer), are pre-
dicted to slightly decrease among men (from 445 to 430)
and remain unchanged among women (from 325 to 321).
Age-standardized rates show different patterns according
to individual sites.
Rates are expected to decrease during the next years for
stomach, colorectal and bladder cancer for both sexes, oral
cavity & pharynx and lung cancer for males, breast, and
ovary cancer for females (Figure 1, dashed lines). Among
men, the largest increase in the burden is observed for
melanoma (+54%), thyroid (+45%), non-Hodgkin lymph-
oma (+43%), and prostate (+37%). Prostate cancer will con-
tribute the largest number of cases (8083) followed by
colorectal cancer (2908) and lung cancer (2791). For
women, cases of lung and oral cavity and pharynx are pro-
jected to increase by +48% and +38%, respectively; those of
thyroid by +45% and non-Hodgkin lymphoma by +36%.
The sites with the most cancer predicted are breast, with
5870 cases, followed by colorectal and lung with over 2000
cases each, melanoma with 1341 cases and corpus uteri
with 1040 cases.
Discussion
In this article we present, for the first time, projections
of the future burden of cancer for all of Switzerland up
to 2019.
Although the age-adjusted incidence rates for all can-
cers combined are expected to decrease slightly between
2009 and 2019 for men and stabilize for women, the
number of cases is predicted to increase substantially in
both sexes. Most of the increase will be driven by the
demographic changes occurring in the Swiss population,
in terms of its growing and ageing. In 2015-2019 the
overall annual cancer burden is predicted to be 46269
Table 2 Actual age-standardized rates and number of cases for 2005-2009 and projections for 2015-2019 in
Switzerland by cancer site and by sex














































17.15 14.53 738 820 11% -17% 28% 6.37 7.04 312 430 38% 18% 20%
Stomach 10.41 7.89 474 478 1% -35% 36% 5.00 4.55 306 330 8% -17% 25%
Colon, Rectum 49.34 45.76 2271 2908 28% -9% 37% 30.55 28.47 1809 2084 15% -9% 24%
Lung, Bronchus,
Trachea
54.43 45.87 2460 2791 13% -22% 35% 26.70 30.83 1380 2036 48% 26% 22%
Skin Melanoma 23.81 28.54 1053 1621 54% 25% 29% 21.06 24.01 1007 1341 33% 17% 16%
Breast 109.88 99.33 5388 5870 9% -10% 19%
Corpus Uteri,
Uterus NOS
16.84 16.80 880 1040 18% -4% 22%
Ovary 11.28 9.68 584 622 6% -15% 22%
Prostate 130.34 130.34 5900 8083 37% 0% 37%
Bladder 18.73 15.38 885 1033 17% -24% 41% 4.53 4.26 289 344 19% -8% 27%
Thyroid 3.55 4.29 149 216 45% 27% 18% 9.26 11.81 406 586 45% 32% 12%
Non Hodgkin
Lymphoma
17.55 19.11 779 1116 43% 12% 31% 12.61 14.07 688 935 36% 14% 21%





445.40 429.85 20005 25910 30% -5% 34% 324.59 320.56 16913 20359 20% -1% 21%
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http://www.biomedcentral.com/1471-2458/14/102new cases in Switzerland, corresponding to an increase
of 30% among men and of 20% among women com-
pared with 2005-2009. In terms of absolute numbers,
the largest increase is expected for cancers of the pros-
tate, with 8083 cases, and breast, with 5870 cases per
year, followed by colorectum and lung with almost 5000
cases each, and melanoma with 2962 cases.
Results from cancer burden projections produced in
other industrialized countries show largely similar pat-
terns to ours. Projections in the USA show an increase
by 26% of all cancers among men and by 18% among
women from 2010 to 2020 [12]. Similarly to ours, the in-
cidence of all cancers combined in the UK started to
level off after a few decades of rise in 1998-2007 and is
projected to fall by 1% in males and by 1.9% in females
from 2007 to 2030. At 2020 the demographic changes
will be responsible for an increase in the number of
cases by 19% in men and 13% in women [13].
While the overall pattern of increase in the burden of
cancer is comparable, there are important differences in
predictions for some specific cancer sites. For lung can-
cer among men, for example, we project in Switzerlanda decrease in the age-standardized rates with a relatively
small increase in the number of cases (+13%) as
compared to the increase projected in the UK and US
(+17% and +29%, respectively). Similarly, among women
we predict an increase in age-standardized rates and a
particularly strong increase in the new cases, +48%.
However, the number of lung cancer cases among
women in the UK and in the USA is expected to in-
crease by only +16% and +23%, respectively [12,13]. A
much larger increase in the number of cases of melan-
oma, non-Hodgkin disease, prostate and thyroid cancer
is also expected in Switzerland, as compared to the UK
and USA [12,13]. The reasons for these disparities are
difficult to explain and may in some part be due to dif-
ferences in data modelling. However, part of the differ-
ence could be attributable to differences in the intensity
of diagnostic procedures between the countries as well
as to differences in the exposure to risk factors, prevent-
ive measures and screening. For example, a reduction in
smoking prevalence has been associated with the de-
crease in cancer of the lung and oral cavity and pharynx
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F
Figure 1 Actual and projected rates for all cancer and individual cancer sites. Thick lines represent actual rates; thin lines represent
projected rates. Crude rates in full line; age- standardised rates in dashed line. Male (M) in blue; female (F) in red.
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http://www.biomedcentral.com/1471-2458/14/102countries) [7,10,14]. In Switzerland a smoking ban has
been set in place for public places only since 2010, much
later compared to other countries, and different smoking
behaviours may explain some of the differences observed
in lung cancer projections with the other countries.
The Swiss health system is particularly strong in the
diagnosis and treatment of cancer patients, which trans-
lates into internationally recognized high survival rates.
However, the system is rather weak in prevention and
health promotion, with spending on health promotion and
prevention at 2.3% of total health expenditure, lower than
the average of 2.7% for all countries of the Organisation
for Economic Co-operation and Development [3]. The
highly decentralised nature of the Swiss health system
has historically made it difficult to deliver broad-based
policies to address major chronic disease risk factors,
such as tobacco smoking, alcohol abuse and obesity.
Similarly, implementing cancer prevention measures with
a proven value has been slow; for example, national
screening programmes for breast cancer or colon cancer
are not in place yet. However, with the confederation
recently strengthening its role in health promotion and
policy programs, there are new opportunities for improv-
ing the impact of such measures.
Future predictions depend on multiple assumptions,
but the basic premise is that past trends will be carriedforward into the future. Any changes in these trends will
mean that the projections will not be realized. As sug-
gested by Møller et al, [7] we modified this assumption
by attenuating the ‘drift’ component of the observed
changes in rates by 25% and, in cases of a significant de-
parture from a linear trend we used only the trend in
most recent 10 years, instead of the average of the whole
period, to project the drift component. The model used
in this paper has been tested and validated in the Nordic
countries, in Canada, the UK and other countries and a
set of conditions found to produce the most accurate
predictions has been applied [7,13,14].
The effects of screening activities are difficult to account
for in cancer projections, and this is especially true for
Switzerland since screening programmes are not uni-
formly applied to the whole country and their initiation is
not necessarily simultaneous. To minimise the impact that
the high levels of PSA screening observed in the nineties
had on cancer trends for prostate cancer we chose to use
the 2005-2009 incidence rate constant, as already done by
other authors [10,11]. For breast cancer, to take into ac-
count possible changes due to the implementation of
screening programmes we modelled the rates separately
for women in screening age from the others.
Another potential problem is due to the fact that
Swiss cancer registries only partially cover the national
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throughout the period considered for model fitting.
The trends used for our predictions were derived from
NICER national figures extrapolated from actual data
recorded in cantons covered by cancer registration.
NICER calculates the average incidence rate in each
linguistic region by pooling cases from the relevant
registries and their populations. This rate is determined
separately by five-year age group, sex and cancer site. It
is applied to the entire linguistic region assuming
homogeneity of data between the geographical areas
that are covered and those that are not covered. The
Swiss estimate published by the Federal Statistical Of-
fice and NICER corresponds to the sum of estimated
cases for each language region. Therefore, the estimates
take into account the specificity of the geographical
areas. However, at the end of 2009 cancer registration
coverage was 61% of the whole country, with good rep-
resentation of all major language regions at almost
100% for French-speaking Switzerland, 100% for the
Italian-speaking region and 40% for the German-
speaking region [4]. The decreasing reliability of cancer
predictions over time is also related to the decreasing
reliability of the population predictions. For population
projections we have chosen the reference scenario re-
producing the demographic changes observed at the
beginning of the 21st century. We did not use those
scenarios that increase the aging population or com-
bine assumptions most favourable to population
growth such as an increase in migration and fertility.
The scenario of increased aging would certainly amplify
the number of cancer cases. Such a scenario must be
kept into account in future assumptions. However,
given the relatively short period of our projections, this
choice should not have introduced any serious error in
this study.
Conclusions
The burden of cancer is expected to increase sharply in
Switzerland over the next 10 years and, unless marked
improvements in cancer therapy and/or prevention strat-
egies emerge, the number of cancer deaths may also grow
substantially. New and more effective preventive mea-
sures should be put in place to counteract the inevitable
increase in the number of cancer cases. Targeting risk
factors such as obesity, physical inactivity, and tobacco
use may result in incidence rates that are lower than
those predicted. These expected rates for all cancers
combined and for individual sites will provide a bench-
mark against which to measure the impact of prevention
strategies in Switzerland.
Measuring the disease burden helps also to estimate
the future needs of health care resources. To address the
expected impact of increasing cancer incidence on theSwiss health care system, several additional interventions
should be planned to prevent a potential shortage of
health professionals, to invest in the infrastructure
needed to deliver cancer care and to avoid an inevitable
increase in cancer costs.
Switzerland has a high level of economic development
and Swiss residents benefit from universal coverage, high
levels of access to services and proximity to health ser-
vices. The challenge for the years ahead will be to de-
velop a system that can respond to the changing health
risks and care needs of Swiss residents.
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